Presentation is loading. Please wait.

Presentation is loading. Please wait.

The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge  Grant C. Nicholson, BSc, Harsha H. Kariyawasam,

Published byMyron McDaniel Modified over 6 years ago

Similar presentations

Presentation on theme: "The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge  Grant C. Nicholson, BSc, Harsha H. Kariyawasam,"— Presentation transcript:

1 The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge  Grant C. Nicholson, BSc, Harsha H. Kariyawasam, MBBS, PhD, Andrew J. Tan, MSc, Jens M. Hohlfeld, MD, Deborah Quinn, MD, Christoph Walker, PhD, David Rodman, MD, John Westwick, PhD, Stipo Jurcevic, PhD, Onn Min Kon, MD, Peter J. Barnes, FMedSci, FRS, Norbert Krug, MD, Trevor T. Hansel, MBBCh, PhD  Journal of Allergy and Clinical Immunology  Volume 128, Issue 4, Pages e9 (October 2011) DOI: /j.jaci Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Overview of study design for the parallel group study that examined the effects of an mAbagainst IL-13 compared with placebo and topical nasal fluticasone propionate. Intravenous anti–IL-13 or intravenous placebo was administered on day 1, while NAC were performed at screening and on days 5, 6, and 7. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 IL-13 levels in SAM eluates from individual subjects in relation to NAC. Anti–IL-13 treatment significantly decreased IL-13 levels when compared with placebo after NAC, expressed as AUC change from baseline (P < .05 on day 5 and P < .01 on day 7). Nasal fluticasone caused decreased IL-13 levels on day 5 (P < .05). Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 IL-5 levels in SAM eluates from individual subjects in relation to NAC. Data for each subject are connected, and each subject has an individual color code that is retained for Figs 2 and 3 in the publication. Nasal fluticasone significantly decreased IL-5 levels expressed as AUC change from baseline after NAC when compared with placebo (P < .01 on day 5). Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 TNSS in relation to NAC recorded from 0 to 8 hours on 4 separate visits (pretreatment/placebo, days 5, 6, and 7). Data are presented as medians at various times. There were no significant effects of anti–IL-13 treatment or fluticasone propionate treatment on TNSS in unselected patients. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig E1 Levels of IL-13, IL-5, and eotaxin measured in SAM eluates are shown as box-whisker plots (median, quartiles, and range). Changes in nasal IL-13 AUC levels were found to be significantly decreased on day 5 (P < .05) and day 7 (P < .01) after anti–IL-13 treatment in comparison with placebo (Table II). Changes in IL-13 AUC levels on day 5 (P < .05) and IL-5 levels on day 5 (P < .01) were found to be significantly decreased after fluticasone propionate treatment versus placebo (Table II). AUC, Area under the curve. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig E2 Eotaxin levels in SAM eluates from individual subjects in relation to NAC. Data for each subject are connected, and each subject has an individual color code that is also retained for Figs 2 and 3 in the published manuscript and in Fig E4. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8 Fig E3 The percentage of eosinophils among leukocytes in nasal lavage is presented. The eosinophil differential was obtained on light microscopy of stained cytospins from nasal lavages. Data are shown as box-whisker plots (median, quartiles, and range). Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

9 Fig E4 TNSS from the cohort receiving anti–IL-13 treatment. Subjects have been separated into high IL-13 (n = 4) and low IL-13 (n = 11) groups based on IL-13 levels measurement from SAM eluates at 7 and 8 hours post-NAC at screening. Post hoc analysis of TNSS between groups (high vs low IL-13 levels at screening) showed a trend for a difference on day 5 (P < .10) (Table E1). Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

10 Fig E5 TNSS from cohort receiving anti–IL-13 treatment. Subjects are separated into high IL-13 and low IL-13 groups based on IL-13 levels measurement from SAM eluates at 7 and 8 hours post-NAC at screening. Data are expressed as medians with quartiles and range. Post hoc analysis of TNSS between groups (high vs low IL-13 levels at screening) showed a trend for a difference on day 5 (P < .10) (Table E1). Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge  Grant C. Nicholson, BSc, Harsha H. Kariyawasam,"

Similar presentations

Nasal challenge with allergen leads to maxillary sinus inflammation

Nasal challenge with allergen leads to maxillary sinus inflammation
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Specificity and reproducibility of nasal biomarkers in patients with allergic rhinitis after allergen challenge chamber exposure  Philipp Badorrek, MD,

Specificity and reproducibility of nasal biomarkers in patients with allergic rhinitis after allergen challenge chamber exposure  Philipp Badorrek, MD,
A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,
Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,
Circulating microRNAs as biomarkers in patients with allergic rhinitis and asthma  Ronaldo P. Panganiban, BS, Yanli Wang, BS, Judie Howrylak, MD, PhD,

Circulating microRNAs as biomarkers in patients with allergic rhinitis and asthma  Ronaldo P. Panganiban, BS, Yanli Wang, BS, Judie Howrylak, MD, PhD,
Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.

Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids  Kittipong Maneechotesuwan, MD, PhD, Sirinya.

Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids  Kittipong Maneechotesuwan, MD, PhD, Sirinya.
Fluticasone furoate nasal spray reduces the nasal-ocular reflex: A mechanism for the efficacy of topical steroids in controlling allergic eye symptoms 

Fluticasone furoate nasal spray reduces the nasal-ocular reflex: A mechanism for the efficacy of topical steroids in controlling allergic eye symptoms 
Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.
Oral steroids and doxycycline: Two different approaches to treat nasal polyps  Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,

Oral steroids and doxycycline: Two different approaches to treat nasal polyps  Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,
The effects of calcitriol treatment in glucocorticoid-resistant asthma

The effects of calcitriol treatment in glucocorticoid-resistant asthma
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms  Natasha C. Gunawardana,

The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms  Natasha C. Gunawardana,
Circulating microRNAs as biomarkers in patients with allergic rhinitis and asthma  Ronaldo P. Panganiban, BS, Yanli Wang, BS, Judie Howrylak, MD, PhD,

Circulating microRNAs as biomarkers in patients with allergic rhinitis and asthma  Ronaldo P. Panganiban, BS, Yanli Wang, BS, Judie Howrylak, MD, PhD,
Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis  Marc E. Rothenberg, MD, PhD, Ting Wen, PhD, Allison Greenberg, BA, Oral.

Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis  Marc E. Rothenberg, MD, PhD, Ting Wen, PhD, Allison Greenberg, BA, Oral.
High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired.

High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired.
As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis  Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis  Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Similar presentations

Ads by Google